nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A1—polycystic ovary syndrome	0.549	1	CbGaD
Sulindac—PTGS2—ovarian follicle—polycystic ovary syndrome	0.00911	0.0725	CbGeAlD
Sulindac—AKR1B1—embryo—polycystic ovary syndrome	0.00654	0.052	CbGeAlD
Sulindac—AKR1B1—adrenal cortex—polycystic ovary syndrome	0.00536	0.0426	CbGeAlD
Sulindac—AKR1B1—endometrium—polycystic ovary syndrome	0.00479	0.0381	CbGeAlD
Sulindac—MAPK3—embryo—polycystic ovary syndrome	0.00474	0.0377	CbGeAlD
Sulindac—CYP1A2—urine—polycystic ovary syndrome	0.0046	0.0366	CbGeAlD
Sulindac—AKR1B1—uterus—polycystic ovary syndrome	0.00441	0.0351	CbGeAlD
Sulindac—AKR1B1—pituitary gland—polycystic ovary syndrome	0.00433	0.0345	CbGeAlD
Sulindac—AKR1B1—adipose tissue—polycystic ovary syndrome	0.00432	0.0343	CbGeAlD
Sulindac—MAPK3—adrenal cortex—polycystic ovary syndrome	0.00389	0.0309	CbGeAlD
Sulindac—AKR1B1—adrenal gland—polycystic ovary syndrome	0.00387	0.0308	CbGeAlD
Sulindac—AKR1B1—female gonad—polycystic ovary syndrome	0.00361	0.0287	CbGeAlD
Sulindac—AKR1B1—vagina—polycystic ovary syndrome	0.00359	0.0285	CbGeAlD
Sulindac—MAPK3—endometrium—polycystic ovary syndrome	0.00347	0.0276	CbGeAlD
Sulindac—PPARD—adipose tissue—polycystic ovary syndrome	0.00339	0.027	CbGeAlD
Sulindac—AKR1B1—endocrine gland—polycystic ovary syndrome	0.00336	0.0267	CbGeAlD
Sulindac—MAPK3—uterus—polycystic ovary syndrome	0.0032	0.0254	CbGeAlD
Sulindac—MAPK3—pituitary gland—polycystic ovary syndrome	0.00314	0.025	CbGeAlD
Sulindac—MAPK3—adipose tissue—polycystic ovary syndrome	0.00313	0.0249	CbGeAlD
Sulindac—PPARD—adrenal gland—polycystic ovary syndrome	0.00304	0.0242	CbGeAlD
Sulindac—PPARD—female gonad—polycystic ovary syndrome	0.00284	0.0226	CbGeAlD
Sulindac—PPARD—vagina—polycystic ovary syndrome	0.00282	0.0224	CbGeAlD
Sulindac—MAPK3—adrenal gland—polycystic ovary syndrome	0.00281	0.0223	CbGeAlD
Sulindac—PPARD—endocrine gland—polycystic ovary syndrome	0.00264	0.021	CbGeAlD
Sulindac—MAPK3—female gonad—polycystic ovary syndrome	0.00262	0.0208	CbGeAlD
Sulindac—MAPK3—vagina—polycystic ovary syndrome	0.0026	0.0207	CbGeAlD
Sulindac—MAPK3—endocrine gland—polycystic ovary syndrome	0.00243	0.0193	CbGeAlD
Sulindac—ALB—adrenal gland—polycystic ovary syndrome	0.00134	0.0106	CbGeAlD
Sulindac—PTGS2—embryo—polycystic ovary syndrome	0.00123	0.0098	CbGeAlD
Sulindac—PTGS2—adrenal cortex—polycystic ovary syndrome	0.00101	0.00803	CbGeAlD
Sulindac—CYP1A1—uterus—polycystic ovary syndrome	0.000989	0.00787	CbGeAlD
Sulindac—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000968	0.00769	CbGeAlD
Sulindac—PTGS1—endometrium—polycystic ovary syndrome	0.000943	0.0075	CbGeAlD
Sulindac—PTGS2—endometrium—polycystic ovary syndrome	0.000902	0.00717	CbGeAlD
Sulindac—PTGS1—uterus—polycystic ovary syndrome	0.000869	0.00691	CbGeAlD
Sulindac—PTGS1—pituitary gland—polycystic ovary syndrome	0.000854	0.00679	CbGeAlD
Sulindac—PTGS1—adipose tissue—polycystic ovary syndrome	0.00085	0.00676	CbGeAlD
Sulindac—PTGS2—uterus—polycystic ovary syndrome	0.000831	0.00661	CbGeAlD
Sulindac—PTGS2—pituitary gland—polycystic ovary syndrome	0.000816	0.00649	CbGeAlD
Sulindac—PTGS2—adipose tissue—polycystic ovary syndrome	0.000813	0.00646	CbGeAlD
Sulindac—CYP1A1—female gonad—polycystic ovary syndrome	0.000809	0.00644	CbGeAlD
Sulindac—CYP1A1—vagina—polycystic ovary syndrome	0.000804	0.0064	CbGeAlD
Sulindac—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000763	0.00607	CbGeAlD
Sulindac—PTGS1—adrenal gland—polycystic ovary syndrome	0.000763	0.00606	CbGeAlD
Sulindac—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000753	0.00599	CbGeAlD
Sulindac—PTGS2—adrenal gland—polycystic ovary syndrome	0.000729	0.0058	CbGeAlD
Sulindac—PTGS1—female gonad—polycystic ovary syndrome	0.000711	0.00565	CbGeAlD
Sulindac—PTGS1—vagina—polycystic ovary syndrome	0.000707	0.00562	CbGeAlD
Sulindac—PTGS2—female gonad—polycystic ovary syndrome	0.00068	0.0054	CbGeAlD
Sulindac—PTGS2—vagina—polycystic ovary syndrome	0.000676	0.00537	CbGeAlD
Sulindac—PTGS1—endocrine gland—polycystic ovary syndrome	0.000661	0.00526	CbGeAlD
Sulindac—PTGS2—endocrine gland—polycystic ovary syndrome	0.000632	0.00503	CbGeAlD
Sulindac—Renal impairment—Metformin—polycystic ovary syndrome	0.000631	0.0453	CcSEcCtD
Sulindac—Pancreatitis—Metformin—polycystic ovary syndrome	0.000509	0.0366	CcSEcCtD
Sulindac—Sweating increased—Metformin—polycystic ovary syndrome	0.000506	0.0363	CcSEcCtD
Sulindac—Neutropenia—Metformin—polycystic ovary syndrome	0.000486	0.0349	CcSEcCtD
Sulindac—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000454	0.0326	CcSEcCtD
Sulindac—Hepatitis—Metformin—polycystic ovary syndrome	0.000416	0.0298	CcSEcCtD
Sulindac—Flushing—Metformin—polycystic ovary syndrome	0.000386	0.0277	CcSEcCtD
Sulindac—Chills—Metformin—polycystic ovary syndrome	0.000373	0.0268	CcSEcCtD
Sulindac—Flatulence—Metformin—polycystic ovary syndrome	0.000357	0.0256	CcSEcCtD
Sulindac—Dysgeusia—Metformin—polycystic ovary syndrome	0.000354	0.0254	CcSEcCtD
Sulindac—Vision blurred—Metformin—polycystic ovary syndrome	0.000341	0.0245	CcSEcCtD
Sulindac—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000336	0.0241	CcSEcCtD
Sulindac—Malaise—Metformin—polycystic ovary syndrome	0.000326	0.0234	CcSEcCtD
Sulindac—Syncope—Metformin—polycystic ovary syndrome	0.000325	0.0233	CcSEcCtD
Sulindac—Palpitations—Metformin—polycystic ovary syndrome	0.00032	0.023	CcSEcCtD
Sulindac—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000318	0.0228	CcSEcCtD
Sulindac—Hypertension—Metformin—polycystic ovary syndrome	0.000312	0.0224	CcSEcCtD
Sulindac—Chest pain—Metformin—polycystic ovary syndrome	0.000308	0.0221	CcSEcCtD
Sulindac—Myalgia—Metformin—polycystic ovary syndrome	0.000308	0.0221	CcSEcCtD
Sulindac—Discomfort—Metformin—polycystic ovary syndrome	0.000304	0.0219	CcSEcCtD
Sulindac—Oedema—Metformin—polycystic ovary syndrome	0.000295	0.0212	CcSEcCtD
Sulindac—Shock—Metformin—polycystic ovary syndrome	0.000291	0.0209	CcSEcCtD
Sulindac—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000289	0.0208	CcSEcCtD
Sulindac—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000286	0.0205	CcSEcCtD
Sulindac—Anorexia—Metformin—polycystic ovary syndrome	0.000282	0.0202	CcSEcCtD
Sulindac—Hypotension—Metformin—polycystic ovary syndrome	0.000276	0.0198	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000269	0.0193	CcSEcCtD
Sulindac—Paraesthesia—Metformin—polycystic ovary syndrome	0.000265	0.019	CcSEcCtD
Sulindac—Dyspnoea—Metformin—polycystic ovary syndrome	0.000263	0.0189	CcSEcCtD
Sulindac—Somnolence—Metformin—polycystic ovary syndrome	0.000263	0.0188	CcSEcCtD
Sulindac—Dyspepsia—Metformin—polycystic ovary syndrome	0.00026	0.0187	CcSEcCtD
Sulindac—Decreased appetite—Metformin—polycystic ovary syndrome	0.000257	0.0184	CcSEcCtD
Sulindac—Fatigue—Metformin—polycystic ovary syndrome	0.000255	0.0183	CcSEcCtD
Sulindac—Constipation—Metformin—polycystic ovary syndrome	0.000253	0.0181	CcSEcCtD
Sulindac—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000243	0.0175	CcSEcCtD
Sulindac—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000242	0.0173	CcSEcCtD
Sulindac—Urticaria—Metformin—polycystic ovary syndrome	0.000235	0.0168	CcSEcCtD
Sulindac—Asthenia—Metformin—polycystic ovary syndrome	0.000212	0.0152	CcSEcCtD
Sulindac—Pruritus—Metformin—polycystic ovary syndrome	0.000209	0.015	CcSEcCtD
Sulindac—Diarrhoea—Metformin—polycystic ovary syndrome	0.000202	0.0145	CcSEcCtD
Sulindac—Dizziness—Metformin—polycystic ovary syndrome	0.000195	0.014	CcSEcCtD
Sulindac—Vomiting—Metformin—polycystic ovary syndrome	0.000188	0.0135	CcSEcCtD
Sulindac—Rash—Metformin—polycystic ovary syndrome	0.000186	0.0134	CcSEcCtD
Sulindac—Dermatitis—Metformin—polycystic ovary syndrome	0.000186	0.0134	CcSEcCtD
Sulindac—Headache—Metformin—polycystic ovary syndrome	0.000185	0.0133	CcSEcCtD
Sulindac—Nausea—Metformin—polycystic ovary syndrome	0.000175	0.0126	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.46e-05	7.9e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.45e-05	7.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RBP4—polycystic ovary syndrome	2.45e-05	7.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT2—polycystic ovary syndrome	2.45e-05	7.86e-05	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.44e-05	7.83e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LPCAT2—polycystic ovary syndrome	2.43e-05	7.82e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SUOX—polycystic ovary syndrome	2.43e-05	7.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SLC2A4—polycystic ovary syndrome	2.42e-05	7.79e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SERPINE1—polycystic ovary syndrome	2.41e-05	7.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.41e-05	7.75e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	2.4e-05	7.73e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SRD5A1—polycystic ovary syndrome	2.4e-05	7.71e-05	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	2.39e-05	7.7e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AR—polycystic ovary syndrome	2.39e-05	7.67e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKR1C1—polycystic ovary syndrome	2.38e-05	7.66e-05	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—polycystic ovary syndrome	2.34e-05	7.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PRL—polycystic ovary syndrome	2.31e-05	7.43e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PNPLA2—polycystic ovary syndrome	2.3e-05	7.41e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	2.3e-05	7.4e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HMMR—polycystic ovary syndrome	2.3e-05	7.38e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—STAR—polycystic ovary syndrome	2.29e-05	7.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—YAP1—polycystic ovary syndrome	2.28e-05	7.34e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	2.28e-05	7.32e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PPARG—polycystic ovary syndrome	2.28e-05	7.32e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ISYNA1—polycystic ovary syndrome	2.26e-05	7.27e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.26e-05	7.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKR1C1—polycystic ovary syndrome	2.26e-05	7.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—POMC—polycystic ovary syndrome	2.25e-05	7.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GAB1—polycystic ovary syndrome	2.25e-05	7.24e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—POMC—polycystic ovary syndrome	2.24e-05	7.22e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—INS—polycystic ovary syndrome	2.23e-05	7.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	2.21e-05	7.11e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SULT2A1—polycystic ovary syndrome	2.19e-05	7.05e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HSD3B1—polycystic ovary syndrome	2.19e-05	7.04e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SRD5A1—polycystic ovary syndrome	2.18e-05	7.02e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.16e-05	6.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—INSR—polycystic ovary syndrome	2.15e-05	6.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—BCL2—polycystic ovary syndrome	2.14e-05	6.87e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—RRM2—polycystic ovary syndrome	2.12e-05	6.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL18—polycystic ovary syndrome	2.1e-05	6.77e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.1e-05	6.75e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGF18—polycystic ovary syndrome	2.1e-05	6.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—NCOR1—polycystic ovary syndrome	2.08e-05	6.7e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—STAR—polycystic ovary syndrome	2.08e-05	6.7e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	2.08e-05	6.7e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—RBP4—polycystic ovary syndrome	2.08e-05	6.68e-05	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—polycystic ovary syndrome	2.07e-05	6.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	2.06e-05	6.64e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.06e-05	6.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRG1—polycystic ovary syndrome	2.06e-05	6.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.05e-05	6.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.05e-05	6.58e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—YAP1—polycystic ovary syndrome	2.05e-05	6.58e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HMMR—polycystic ovary syndrome	2.04e-05	6.55e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—GNAS—polycystic ovary syndrome	2.02e-05	6.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.01e-05	6.48e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—LHB—polycystic ovary syndrome	2e-05	6.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PGR—polycystic ovary syndrome	1.99e-05	6.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	1.97e-05	6.34e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NAMPT—polycystic ovary syndrome	1.97e-05	6.32e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.96e-05	6.3e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.95e-05	6.28e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HSD3B2—polycystic ovary syndrome	1.95e-05	6.28e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HSD3B1—polycystic ovary syndrome	1.94e-05	6.25e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP11A1—polycystic ovary syndrome	1.94e-05	6.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—polycystic ovary syndrome	1.94e-05	6.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NCOR1—polycystic ovary syndrome	1.94e-05	6.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—NR3C1—polycystic ovary syndrome	1.93e-05	6.2e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.93e-05	6.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	1.92e-05	6.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	1.92e-05	6.18e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.92e-05	6.18e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—GAB1—polycystic ovary syndrome	1.91e-05	6.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRG1—polycystic ovary syndrome	1.9e-05	6.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKR1C1—polycystic ovary syndrome	1.89e-05	6.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NAMPT—polycystic ovary syndrome	1.86e-05	5.99e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HMMR—polycystic ovary syndrome	1.86e-05	5.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PLAT—polycystic ovary syndrome	1.85e-05	5.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GHRL—polycystic ovary syndrome	1.85e-05	5.96e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	1.85e-05	5.95e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKR1C3—polycystic ovary syndrome	1.83e-05	5.9e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	1.82e-05	5.85e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—polycystic ovary syndrome	1.81e-05	5.82e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP17A1—polycystic ovary syndrome	1.8e-05	5.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—polycystic ovary syndrome	1.78e-05	5.71e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—LHB—polycystic ovary syndrome	1.77e-05	5.7e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HSD3B1—polycystic ovary syndrome	1.77e-05	5.7e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ATF1—polycystic ovary syndrome	1.77e-05	5.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IRS2—polycystic ovary syndrome	1.76e-05	5.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CRP—polycystic ovary syndrome	1.76e-05	5.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—polycystic ovary syndrome	1.75e-05	5.64e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.75e-05	5.63e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.75e-05	5.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SULT2A1—polycystic ovary syndrome	1.74e-05	5.59e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKR1C3—polycystic ovary syndrome	1.74e-05	5.59e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HSD3B2—polycystic ovary syndrome	1.73e-05	5.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.72e-05	5.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTHFR—polycystic ovary syndrome	1.71e-05	5.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TNRC6B—polycystic ovary syndrome	1.71e-05	5.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—RRM2—polycystic ovary syndrome	1.69e-05	5.42e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKR1C1—polycystic ovary syndrome	1.68e-05	5.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.66e-05	5.34e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	1.66e-05	5.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NGFR—polycystic ovary syndrome	1.63e-05	5.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IRS2—polycystic ovary syndrome	1.63e-05	5.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—YAP1—polycystic ovary syndrome	1.62e-05	5.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—POMC—polycystic ovary syndrome	1.62e-05	5.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PRL—polycystic ovary syndrome	1.62e-05	5.2e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—LHB—polycystic ovary syndrome	1.62e-05	5.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	1.61e-05	5.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HSD3B2—polycystic ovary syndrome	1.58e-05	5.08e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TH—polycystic ovary syndrome	1.56e-05	5.02e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NAMPT—polycystic ovary syndrome	1.56e-05	5.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.56e-05	5.01e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.55e-05	4.99e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SULT2A1—polycystic ovary syndrome	1.54e-05	4.97e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP11A1—polycystic ovary syndrome	1.54e-05	4.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IRS1—polycystic ovary syndrome	1.54e-05	4.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.53e-05	4.94e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.53e-05	4.92e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKR1C1—polycystic ovary syndrome	1.53e-05	4.92e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	1.53e-05	4.91e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC2A4—polycystic ovary syndrome	1.52e-05	4.89e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—RRM2—polycystic ovary syndrome	1.5e-05	4.81e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PPARG—polycystic ovary syndrome	1.49e-05	4.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TCF7L2—polycystic ovary syndrome	1.46e-05	4.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	1.46e-05	4.69e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKR1C3—polycystic ovary syndrome	1.46e-05	4.68e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—polycystic ovary syndrome	1.45e-05	4.67e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	1.44e-05	4.64e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.44e-05	4.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC2A4—polycystic ovary syndrome	1.44e-05	4.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP17A1—polycystic ovary syndrome	1.43e-05	4.61e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP19A1—polycystic ovary syndrome	1.43e-05	4.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT2—polycystic ovary syndrome	1.42e-05	4.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GNAS—polycystic ovary syndrome	1.42e-05	4.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IRS1—polycystic ovary syndrome	1.42e-05	4.57e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SULT2A1—polycystic ovary syndrome	1.41e-05	4.53e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	1.39e-05	4.45e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.38e-05	4.43e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PRL—polycystic ovary syndrome	1.37e-05	4.42e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	1.37e-05	4.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—RRM2—polycystic ovary syndrome	1.36e-05	4.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—INS—polycystic ovary syndrome	1.36e-05	4.38e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.36e-05	4.37e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.36e-05	4.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—SERPINE1—polycystic ovary syndrome	1.35e-05	4.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRG1—polycystic ovary syndrome	1.33e-05	4.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT2—polycystic ovary syndrome	1.32e-05	4.23e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—YAP1—polycystic ovary syndrome	1.31e-05	4.23e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IGF1—polycystic ovary syndrome	1.31e-05	4.21e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT2—polycystic ovary syndrome	1.31e-05	4.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	1.3e-05	4.18e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	1.29e-05	4.15e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GNAS—polycystic ovary syndrome	1.27e-05	4.1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	1.27e-05	4.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NAMPT—polycystic ovary syndrome	1.26e-05	4.06e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.26e-05	4.04e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—polycystic ovary syndrome	1.25e-05	4.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SERPINE1—polycystic ovary syndrome	1.25e-05	4.02e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	1.25e-05	4.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BCL2—polycystic ovary syndrome	1.24e-05	4e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	1.24e-05	3.99e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TH—polycystic ovary syndrome	1.24e-05	3.99e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	1.24e-05	3.99e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.24e-05	3.98e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.23e-05	3.94e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NCOR1—polycystic ovary syndrome	1.21e-05	3.91e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC2A4—polycystic ovary syndrome	1.21e-05	3.88e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	1.18e-05	3.79e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.16e-05	3.73e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	1.16e-05	3.73e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP1A1—polycystic ovary syndrome	1.15e-05	3.7e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NCOR1—polycystic ovary syndrome	1.15e-05	3.7e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IRS2—polycystic ovary syndrome	1.14e-05	3.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP19A1—polycystic ovary syndrome	1.13e-05	3.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	1.13e-05	3.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRG1—polycystic ovary syndrome	1.13e-05	3.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—LEP—polycystic ovary syndrome	1.12e-05	3.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—polycystic ovary syndrome	1.11e-05	3.56e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	1.1e-05	3.55e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TH—polycystic ovary syndrome	1.1e-05	3.54e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MTHFR—polycystic ovary syndrome	1.07e-05	3.45e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	1.07e-05	3.44e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	1.07e-05	3.44e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTHFR—polycystic ovary syndrome	1.02e-05	3.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GNAS—polycystic ovary syndrome	1.01e-05	3.25e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	1.01e-05	3.24e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TH—polycystic ovary syndrome	1e-05	3.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IRS1—polycystic ovary syndrome	9.95e-06	3.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	9.85e-06	3.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	9.76e-06	3.14e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IRS2—polycystic ovary syndrome	9.68e-06	3.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NCOR1—polycystic ovary syndrome	9.64e-06	3.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—POMC—polycystic ovary syndrome	9.58e-06	3.08e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	9.54e-06	3.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—INS—polycystic ovary syndrome	9.53e-06	3.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1—polycystic ovary syndrome	9.22e-06	2.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT2—polycystic ovary syndrome	9.21e-06	2.96e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	9.19e-06	2.96e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	9.17e-06	2.95e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1A1—polycystic ovary syndrome	9.14e-06	2.94e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	8.98e-06	2.89e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	8.83e-06	2.84e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	8.78e-06	2.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.75e-06	2.81e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	8.72e-06	2.8e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—polycystic ovary syndrome	8.7e-06	2.8e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	8.66e-06	2.78e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—POMC—polycystic ovary syndrome	8.58e-06	2.76e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	8.56e-06	2.75e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	8.54e-06	2.75e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—INS—polycystic ovary syndrome	8.54e-06	2.75e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—polycystic ovary syndrome	8.52e-06	2.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IRS1—polycystic ovary syndrome	8.45e-06	2.72e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	8.24e-06	2.65e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GNAS—polycystic ovary syndrome	8.19e-06	2.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	8.11e-06	2.61e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—INS—polycystic ovary syndrome	8.09e-06	2.6e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT2—polycystic ovary syndrome	7.82e-06	2.52e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NCOR1—polycystic ovary syndrome	7.8e-06	2.51e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	7.56e-06	2.43e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SERPINE1—polycystic ovary syndrome	7.43e-06	2.39e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	7.39e-06	2.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—polycystic ovary syndrome	7.05e-06	2.27e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TH—polycystic ovary syndrome	7.02e-06	2.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—polycystic ovary syndrome	6.91e-06	2.22e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—polycystic ovary syndrome	6.89e-06	2.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	6.82e-06	2.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—POMC—polycystic ovary syndrome	6.81e-06	2.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—INS—polycystic ovary syndrome	6.78e-06	2.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—polycystic ovary syndrome	6.44e-06	2.07e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	6.42e-06	2.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	6.13e-06	1.97e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	6.05e-06	1.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.02e-06	1.94e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—INS—polycystic ovary syndrome	6.01e-06	1.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—polycystic ovary syndrome	5.95e-06	1.91e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	5.73e-06	1.84e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—polycystic ovary syndrome	5.59e-06	1.8e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—POMC—polycystic ovary syndrome	5.51e-06	1.77e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—INS—polycystic ovary syndrome	5.48e-06	1.76e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	5.46e-06	1.75e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	5.17e-06	1.66e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	4.82e-06	1.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—polycystic ovary syndrome	4.16e-06	1.34e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	3.91e-06	1.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	3.86e-06	1.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—INS—polycystic ovary syndrome	3.83e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—polycystic ovary syndrome	3.54e-06	1.14e-05	CbGpPWpGaD
